Background Icotrokinra, a targeted oral peptide that precisely blocks the interleukin-23 receptor, is approved to treat adult and pediatric (≥12 years, ≥40 kg) patients with moderate-to-severe plaque psoriasis (PsO). Objective Assess psoriatic arthritis (PsA)–specific outcomes through Week (W) 16 in a subgroup of phase...
I. McInnes, L. Stein-Gold, R. Bissonnette et al.· Journal of Psoriasis and Pso...· 0 citations
OBJECTIVES
To evaluate the long-term efficacy of bimekizumab in patients with psoriatic arthritis (PsA) across the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains, PsA-related conditions, and comorbidities.
METHODS
Post hoc analysis of pooled data from BE OPTIMAL (NCT03895203;...
A. Deodhar, Alice B. Gottlieb, J. Merola et al.· Rheumatology· 0 citations
INTRODUCTION
In the phase 3 SELECT-PsA 1 study, treatment with upadacitinib (UPA), an oral Janus kinase (JAK) inhibitor, improved signs and symptoms of psoriatic arthritis (PsA) from weeks 12 through 152. We now report the long-term extension phase, evaluating safety and efficacy of upadacitinib versus adalimumab (ADA)...
I. McInnes, Koji Kato, Marina N. Magrey et al.· Rheumatology and Therapy· 0 citations
Abstract Objective This post hoc analysis of the SELECT-PsA 2 study evaluated long-term efficacy and safety of upadacitinib 15 mg once daily in patients with psoriatic arthritis (PsA) and exposure to one prior tumour necrosis factor inhibitor (TNFi). Methods Patients were randomised to upadacitinib 15 mg once daily or...
L. Coates, P. Mease, A. Kavanaugh et al.· RMD Open· 0 citations
Background Obesity represents a state of chronic low-grade inflammation, yet comprehensive comparative analyses examining systemic inflammatory markers across multiple immune-mediated inflammatory diseases (IMIDs) in relation to body mass index (BMI) categories remain limited. We evaluated how obesity-associated inflam...
Stephen A. Shields, Ann Von Holle, R. Padival et al.· Frontiers in Endocrinology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.